InflaRx N.V. (NASDAQ:IFRX) Receives Average Rating of “Moderate Buy” from Analysts

by · The Markets Daily

InflaRx N.V. (NASDAQ:IFRX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $7.00.

Several equities research analysts have commented on the company. Oppenheimer initiated coverage on InflaRx in a report on Friday, April 24th. They issued an “outperform” rating and a $5.00 target price on the stock. HC Wainwright lifted their price target on InflaRx from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Guggenheim reiterated a “buy” rating and issued a $14.00 price target on shares of InflaRx in a research note on Tuesday, April 21st. Raymond James Financial upgraded shares of InflaRx from an “outperform” rating to a “strong-buy” rating and upped their price target for the stock from $7.00 to $9.00 in a research note on Wednesday, May 13th. Finally, Wall Street Zen raised shares of InflaRx from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th.

Get Our Latest Analysis on InflaRx

InflaRx Stock Performance

Shares of InflaRx stock opened at $2.24 on Friday. InflaRx has a 52-week low of $0.74 and a 52-week high of $2.95. The stock has a market capitalization of $161.93 million, a price-to-earnings ratio of -3.15 and a beta of 2.44. The company has a fifty day moving average of $2.11 and a 200-day moving average of $1.39.

InflaRx (NASDAQ:IFRX – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.08. On average, equities research analysts forecast that InflaRx will post -0.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On InflaRx

Institutional investors have recently made changes to their positions in the company. Suvretta Capital Management LLC increased its position in shares of InflaRx by 22.4% during the fourth quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after acquiring an additional 1,450,000 shares in the last quarter. 683 Capital Management LLC boosted its stake in InflaRx by 47.3% during the 4th quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company’s stock valued at $3,348,000 after purchasing an additional 1,065,000 shares during the last quarter. Bank of America Corp DE purchased a new stake in InflaRx during the 3rd quarter valued at $3,316,000. Eversept Partners LP increased its holdings in shares of InflaRx by 1.5% in the 4th quarter. Eversept Partners LP now owns 1,757,312 shares of the company’s stock worth $1,775,000 after purchasing an additional 26,677 shares in the last quarter. Finally, Woodline Partners LP purchased a new position in shares of InflaRx in the first quarter worth $766,000. Hedge funds and other institutional investors own 42.39% of the company’s stock.

About InflaRx

(Get Free Report)

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.

Featured Articles